Dr Sam's Rotation
Follow us on
  • Daily Dose
  • Events
  • Links
  • About
  • Contact Us
  • Calendar

To approve or not approve new inhaled diabetes drug, Afrezza?

4/10/2014

1 Comment

 
MannKind's Afrezza
Pfizer's Exubera
According to a L.A. Times article, a new drug named Afrezza from MannKind Corporation will be considered for approval by the FDA for diabetes and has a different route of administration. The drug is a drug-device combination product, in the form of an inhaler (picture above left). It is a rapid-acting insulin and it is to be administered at the start of the meal. The drug dissolves immediately upon inhalation and enters the bloodstream. Peak insulin blood levels are achieved within 12-15 minutes of administration, mimicking the release of insulin in individuals without diabetes. The main thing MannKind is advocating is the injection-free delivery, which no doubt, would be more appealing to patients with diabetes.

MannKind Corporation was able to win over the advisors to the Food and Drug Administration (FDA). However, the FDA does not have to follow their advisors’ recommendations. The FDA is concerned that the drug may affect lung function. The advisors counter that the inhaled drug is a beneficial alternative to insulin injections and outweigh the FDA’s concerns. It has been a long road for MannKind, as the company has spent over seven years to gain approval for the treatment. The FDA has already rejected this treatment twice.

The FDA has now delayed its decision on Afrezza by three months, until July 15, 2014. Though the FDA historically has followed its advisors’ recommendations, this time frame is to allow the FDA ample time to go over the data that has been provided by MannKind on this drug, as certain dosing and safety questions still remain.

In July 2006, Pfizer came out with an inhaled insulin called Exubera. The device was quite large and inconvenient for the patient. It was about the size of a flashlight (picture above on right). The same question remains for Afrezza, would the inhaled route of delivery prove as effective as injecting insulin through a needle? Regulators saw that only 10% of the insulin got inhaled into the bloodstream, which left them wondering what long-term effect the other 90% would have on the lungs. Exubera came with a label that warned against smoker use, asthmatics use, and recommended regular lung examinations. Diabetes specialists said it was difficult to use because it came in units that were unusual and there were no advantages over less-expensive therapies. One of the biggest cons was that the device could be compared to a bong for smoking marijuana, which could be embarrassing to use in public. Also, compared to showing a patient how to use an insulin pen in five minutes, it would take about an hour to teach a patient to use Exubera. Pfizer’s drug ultimately failed, and it is still unclear if other insulin products that are inhaled will succeed, where Exubera did not.

Would you recommend this new inhaled insulin to your patient?

Posted by: Katherine Tang, PharmD Candidate 2015
1 Comment
Robert Sacher
4/10/2014 09:04:40 am

Your article is poorly worded.

Do you mean would you recommend Afrezza or Exubera? You spent almost as many words on Exubera as you did on Afrezza.

I know your intent but you cannot assume everyone will follow your logic. Be more precise and write more about Afrezza is that is indeed the drug to which you are referring.

Thank you.

Reply



Leave a Reply.


    Archives

    February 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    November 2013
    October 2013
    September 2013
    August 2013
    June 2013
    May 2013
    April 2013

    Categories

    All
    Books
    Clinical
    Continuing Education
    Dr Sam Post
    Management
    Over The Counter
    Parkinson's Disease
    Student Post
    Technology
    Web Site

    Enter your email address to subscribe to our blog:

    Delivered by FeedBurner

    RSS Feed

Proudly powered by Weebly